U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22N6O3
Molecular Weight 418.4485
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FUTIBATINIB

SMILES

[H][C@@]1(CCN(C1)C(=O)C=C)N2N=C(C#CC3=CC(OC)=CC(OC)=C3)C4=C(N)N=CN=C24

InChI

InChIKey=KEIPNCCJPRMIAX-HNNXBMFYSA-N
InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1

HIDE SMILES / InChI

Approval Year

2022
358
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 3.9 nM [IC50]
Inhibitor
8297
 1.3 nM [IC50]
Inhibitor
8297
 1.6 nM [IC50]
Inhibitor
8297
 8.3 nM [IC50]
PubMed

PubMed

TitleDatePubMed
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
2019 Aug
Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.
2019 Dec
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure.
2019 Feb 19
Name Type Language
FUTIBATINIB
USAN   INN  
Official Name English
LYTGOBI
Brand Name English
Futibatinib [WHO-DD]
Common Name English
FUTIBATINIB [USAN]
Common Name English
futibatinib [INN]
Common Name English
FGFR-IN-1
Common Name English
TAS-120
Code English
FUTIBATINIB [JAN]
Common Name English
2-PROPEN-1-ONE, 1-((3S)-3-(4-AMINO-3-(2-(3,5-DIMETHOXYPHENYL)ETHYNYL)-1H-PYRAZOLO(3,4-D)PYRIMIDIN-1-YL)-1-PYRROLIDINYL)-
Systematic Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/19/2146
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
FDA ORPHAN DRUG 635018
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
Code System Code Type Description
CAS
1814961-20-0
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
NO STRUCTURE GIVEN
FDA UNII
4B93MGE4AL
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
PRIMARY
SMS_ID
100000180711
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
PRIMARY
DAILYMED
4B93MGE4AL
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
PRIMARY
USAN
GH-182
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
PRIMARY
INN
10879
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
PRIMARY
NCI_THESAURUS
C114283
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
PRIMARY
DRUG BANK
DB15149
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
PRIMARY
CAS
1448169-71-8
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
PRIMARY
PUBCHEM
71621331
Created by admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of FUTIBATINIB
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966